Plain-English translation of NCT07547228 on ClinicalTrials.gov ā Ā· Source last updated Ā· Translation generated Ā· How we translate trials
Phase 1/2 ā A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help people with a serious eye condition called neovascular age-related macular degeneration (nAMD) that has not improved with standard treatments. The medication is given as injections directly into the eye. Researchers want to find out if this treatment is safe and whether it can help preserve or improve vision.
Many people with nAMD continue to lose vision even after receiving standard injectable treatments. This trial exists to see whether this new medication could offer hope to patients whose eyes have stopped responding to currently available options.
You likely qualify ifā¦
You likely don't qualify ifā¦
You will receive three injections of the medication (or placebo) into your eye over the first 4 weeks, spaced 2 weeks apart. You'll have eye exams and blood tests at each injection visit and then every 4 weeks for the following 5 months to watch for any side effects and measure whether your vision improves. The entire study lasts about 6 months. Before starting, you may need to wait several weeks after your last standard eye treatment so it clears from your system.
AI-generated summary from trial data Ā· Jun 15, 2026 Ā· Not medical advice
Singapore